
AODT-0050
Cagrilintide + Semaglutide (CagriSema)
Next-gen weight loss combination. Dual mechanism targeting GLP-1 and amylin receptors for superior fat reduction.
- CAS
- —
- Purity
- ≥99.15% each
- Grade
- Research
Priority Sales Hotline
Tap to chat with us

AODT-0050
Next-gen weight loss combination. Dual mechanism targeting GLP-1 and amylin receptors for superior fat reduction.
We use cookies
We use essential cookies to make our site work, and optional analytics & preference cookies to improve your experience. See our Cookie Policy.